Boulevard Bio Launches with $65 Million

Company: Boulevard Bio · Event Type: Deal and Financing · Product/Asset: BLVD101 · Subject: Autoimmune Disease · Event Date: August 12, 2026 Summary Boulevard Bio emerged from stealth with approximately $65 million in aggregate equity and convertible-note financing from Deerfield and affiliates. Its precision-immunology pipeline…